|

Multidisciplinary Dissection of Renal and Metabolic Effects of Glyfozines on Elderly Patients: From Molecular Aspects to Clinical Indications

RECRUITINGSponsored by Chiara Lanzani
Actively Recruiting
SponsorChiara Lanzani
Started2025-02-14
Est. completion2026-11
Eligibility
Age65 Years+

Summary

The project aims to study the impact of SGLT2i therapy on clinical and biochemical aspects. in elderly. The project will combine different types of data, such as clinical and biological information, and will use advanced Bayesian statistical methods to understand the relationship between risk factors and patient outcomes following treatment with SGLT2 inhibitors.

Eligibility

Age: 65 Years+
Inclusion Criteria:

1. Participant is willing and able to give informed consent for participation in the study;
2. Patients must be enrolled also in MED-Cli e MED-Mol studies by signing both the MED-Cli e MED-Mol informed consents.
3. The medical product is the standard of care for the patient and has been prescribed according to clinical practice and independent of the present study;
4. Age ≥65 years;
5. Participant has not yet started the prescribed SGLT2i therapy;
6. Participant has at least one clinical indication for SGLT2i use according to clinical practice guidelines.

Exclusion Criteria:

1. Current or previous use of SGLT2i;
2. Inability to sign the informed consent.

Conditions6

DiabetesDiabetes (DM)Elderly Patients (>65 Years)Heart DiseaseInternal DiseaseRenal Diseases

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.